1257443-69-8

Basic information

• Product Name: (R)-6-(1-(biphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylcarbamoyl)pyrimidine-4-carboxylic acid
• Synonyms: (R)-6-(1-(biphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylcarbamoyl)pyrimidine-4-carboxylic acid
• CAS NO: 1257443-69-8
• Molecular Weight: 433.464
• Mol File: 1257443-69-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (R)-6-(1-(biphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylcarbamoyl)pyrimidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-6-(1-(biphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylcarbamoyl)pyrimidine-4-carboxylic acid(1257443-69-8)
• EPA Substance Registry System: (R)-6-(1-(biphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylcarbamoyl)pyrimidine-4-carboxylic acid(1257443-69-8)

Safety Data

• Hazardous Substances Data: 1257443-69-8(Hazardous Substances Data)

Upstream product

• 16490-02-1 pyrimidine-4,6-dicarboxylic acid 
• 1257443-01-8 ethyl (R)-3-amino-4-(biphenyl-4-yl)butyrate hydrochloride 
• 1257443-00-7 (R)-ethyl 4-(biphenyl-4-yl)-3-(tert-butoxycarbonylamino)butanoate 
• 331763-75-8 (R)-4-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)butanoic acid 
• 98-80-6 phenylboronic acid 
• 1257446-29-9 (R)-ethyl 4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoate 

Relevant articles and documents

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.